Integra LifeSciences (NASDAQ:IART) Hits New 12-Month High – Here’s Why

Shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) hit a new 52-week high during trading on Thursday . The company traded as high as $16.50 and last traded at $16.3890, with a volume of 676230 shares traded. The stock had previously closed at $15.19.

Analysts Set New Price Targets

A number of analysts recently commented on the company. Citigroup upgraded Integra LifeSciences from a “sell” rating to a “neutral” rating and lifted their price objective for the stock from $11.00 to $16.00 in a research report on Thursday. Wall Street Zen upgraded Integra LifeSciences from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. Wells Fargo & Company lifted their price objective on Integra LifeSciences from $12.00 to $15.00 and gave the stock an “equal weight” rating in a research report on Wednesday, May 6th. Weiss Ratings upgraded Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, May 13th. Finally, Truist Financial lowered their price objective on Integra LifeSciences from $13.00 to $12.00 and set a “hold” rating for the company in a research report on Wednesday, April 15th. Four investment analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Reduce” and a consensus target price of $14.00.

Integra LifeSciences Price Performance

The company has a market capitalization of $1.28 billion, a price-to-earnings ratio of -2.55, a price-to-earnings-growth ratio of 1.05 and a beta of 1.08. The company has a 50-day moving average price of $11.47 and a 200-day moving average price of $11.78. The company has a debt-to-equity ratio of 1.75, a quick ratio of 1.95 and a current ratio of 3.38.

Integra LifeSciences (NASDAQ:IART) last posted its earnings results on Tuesday, May 5th. The life sciences company reported $0.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.41 by $0.13. The company had revenue of $391.92 million during the quarter, compared to analyst estimates of $381.81 million. Integra LifeSciences had a positive return on equity of 17.42% and a negative net margin of 30.15%.The company’s revenue for the quarter was up 2.4% compared to the same quarter last year. During the same period in the previous year, the company earned $0.41 EPS. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. On average, equities research analysts expect that Integra LifeSciences Holdings Corporation will post 2.44 EPS for the current fiscal year.

Hedge Funds Weigh In On Integra LifeSciences

Several institutional investors and hedge funds have recently modified their holdings of IART. Global Retirement Partners LLC acquired a new position in shares of Integra LifeSciences in the 4th quarter valued at approximately $25,000. Osaic Holdings Inc. grew its position in shares of Integra LifeSciences by 36.6% in the 2nd quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock valued at $51,000 after purchasing an additional 1,104 shares during the period. GAMMA Investing LLC grew its position in shares of Integra LifeSciences by 145.9% in the 4th quarter. GAMMA Investing LLC now owns 6,307 shares of the life sciences company’s stock valued at $78,000 after purchasing an additional 3,742 shares during the period. Tower Research Capital LLC TRC grew its position in shares of Integra LifeSciences by 595.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 7,958 shares of the life sciences company’s stock valued at $98,000 after purchasing an additional 6,814 shares during the period. Finally, Virtu Financial LLC acquired a new position in shares of Integra LifeSciences in the 4th quarter valued at approximately $124,000. 84.78% of the stock is currently owned by institutional investors and hedge funds.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.